Positive allosteric modulation of AMPA receptors via PF4778574 leads to reduced demyelination and clinical disability in experimental models of multiple sclerosis
PF4778574 demonstrates promise in mitigating EAE effects, especially in terms of clinical disability and demyelination. These results suggest AMPA-PAMs as potential targets of interest for MS treatment beyond immunomodulatory approaches.
Authors
- Thomas Kurz (ORCID: https://orcid.org/0000-0002-9474-4224)
- Andrea Issberner
- Mustafa Sindi (ORCID: https://orcid.org/0009-0008-2890-2336)
- Sven Guenther Meuth (ORCID: https://orcid.org/0000-0003-2571-3501)
- Tobias Ruck (ORCID: https://orcid.org/0000-0001-6332-8650)
- Joel Gruchot (ORCID: https://orcid.org/0000-0003-4894-4679)
- Patrick Küry (ORCID: https://orcid.org/0000-0002-2654-1126)
- John Silbereis
- Michael Dietrich (ORCID: https://orcid.org/0000-0001-6794-3618)
- Holger Stark (ORCID: https://orcid.org/0000-0003-3336-1710)
- Diana Klees
- A Philipp
- Hans Hartung
- Christina Hecker
Institutions
- The University of Sydney (AU)
- Biogen (United States) (US)
- Düsseldorf University Hospital (DE)
- Kliniken Maria Hilf (DE)
- Heinrich Heine University Düsseldorf (DE)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1532877
- Citations
- 2
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82